In the fast-expanding healthtech landscape, with a constant stream of new products entering the market, a company's intellectual property (IP)—the secret sauce that differentiates their technology from competitors' offerings—holds more value than ever.
The IP battle between telehealth players Amwell and Teladoc - sparked off five years ago and ongoing with new allegations cropping up - is an example of the legal minefield that healthtech firms are entering. More often than not, if such legal wrangles happen, it is the smaller players that come off worst.
Alison outlines what companies should do to protect their IP, including regarding their software programs and databases.
Read the full version originally published by First Word MedTech on 7 October (subscription required).
